Pharming receives positive opinion for Rhucin

Thursday 24 June 2010

The Pharming Group NV said that its recombinant human C1 inhibitor for hereditary angioedema, Rhucin, has received a positive opinion from the European Medicines Agency. This ends a three-year effort to gain regulatory approval for the drug.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Netherlands